Prellis utilizes holographic tissue printing technology to create 3D lymph node organoids that replicate human immune responses, enabling the discovery of fully human antibodies with low immunogenicity risk. This approach addresses the challenge of efficiently identifying diverse therapeutic candidates by integrating machine learning with in vitro human biology.
Funding
$79.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
+3Founders
Product
Problem
Traditional antibody discovery methods often rely on animal models or in vitro systems that fail to fully replicate the complexity of the human immune system. This can lead to the development of therapeutic antibodies with limited efficacy or potential immunogenicity issues in humans. Identifying diverse and effective antibody candidates remains a significant challenge in drug development.
Solution
Prellis leverages holographic tissue printing to create 3D lymph node organoids (LNOs) that mimic the human immune system in vitro. The LNO platform enables the discovery of fully human antibodies by exploiting the genetic diversity from multiple blood donors, accessing a vast immune repertoire with low immunogenicity risk. By integrating these bioprinted organoids with machine learning, Prellis can efficiently screen and optimize antibody candidates, accelerating the development of next-generation therapeutics. The EXIS™ platform recaptures human immune biology in 3D-printed organoids for the rapid discovery of diverse antibodies.
Target Audience
The primary target audience includes biotech and pharmaceutical companies seeking to accelerate antibody discovery and develop novel therapeutic agents with enhanced treatment outcomes.
Features
- Two-photon holography generates intricate 3D bioprinted scaffolds that recapitulate complex biology in the form of organoids.
- Integration of lab experiments with state-of-the-art machine learning to efficiently guide the discovery of optimal antibody candidates.
- In vitro platform replicates in vivo lymph node processes using 3D lymph node organoids, enabling rapid and scalable mAb discovery.
- Accesses a vast immune repertoire for fully human antibody discovery with low immunogenicity risk.
- AI-enhanced screening streamlines the path from lab to clinic.